# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price ta...
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate ...
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price ta...
Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial programAgreement also ...
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate ...